[go: up one dir, main page]

MA39211B1 - Composés tricycliques comme agents anti-cancers - Google Patents

Composés tricycliques comme agents anti-cancers

Info

Publication number
MA39211B1
MA39211B1 MA39211A MA39211A MA39211B1 MA 39211 B1 MA39211 B1 MA 39211B1 MA 39211 A MA39211 A MA 39211A MA 39211 A MA39211 A MA 39211A MA 39211 B1 MA39211 B1 MA 39211B1
Authority
MA
Morocco
Prior art keywords
tricyclic compounds
cancer agents
compounds
tricyclic
treatment
Prior art date
Application number
MA39211A
Other languages
English (en)
Other versions
MA39211A1 (fr
Inventor
Ashvinikumar V Gavai
George V Delucca
Daniel O'malley
Patrice Gill
Claude A Quesnelle
Francis Y Lee
John S Tokarski
Derek J Norris
Wayne Vaccaro
Mikkel V Debenedetto
Andrew P Degnan
Haiquan Fang
Matthew D Hill
Hong Huang
William D Schmitz
John E Starrett
Wen-Ching Han
Sunil Kumar Mandal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA39211A1 publication Critical patent/MA39211A1/fr
Publication of MA39211B1 publication Critical patent/MA39211B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés tricycliques (i), des compositions pharmaceutiquement acceptables contenant des composés de l'invention et des procédés d'utilisation desdites compositions dans le traitement de divers troubles.
MA39211A 2013-12-24 2014-12-23 Composés tricycliques comme agents anti-cancers MA39211B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24
PCT/US2014/072031 WO2015100282A1 (fr) 2013-12-24 2014-12-23 Composés tricycliques comme agents anti-cancers

Publications (2)

Publication Number Publication Date
MA39211A1 MA39211A1 (fr) 2018-08-31
MA39211B1 true MA39211B1 (fr) 2019-01-31

Family

ID=52293305

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39211A MA39211B1 (fr) 2013-12-24 2014-12-23 Composés tricycliques comme agents anti-cancers

Country Status (34)

Country Link
US (1) US20160318928A1 (fr)
EP (2) EP3087071B1 (fr)
JP (2) JP6466456B2 (fr)
KR (1) KR102457145B1 (fr)
CN (2) CN106029663B (fr)
AR (2) AR099379A1 (fr)
AU (1) AU2014369982B2 (fr)
BR (1) BR112016013744B1 (fr)
CA (1) CA2934953C (fr)
CL (1) CL2016001629A1 (fr)
CY (2) CY1121076T1 (fr)
DK (2) DK3087071T3 (fr)
EA (2) EA032469B1 (fr)
ES (2) ES2698998T3 (fr)
HR (2) HRP20181849T1 (fr)
HU (2) HUE041719T2 (fr)
IL (1) IL246359B (fr)
LT (2) LT3087071T (fr)
MA (1) MA39211B1 (fr)
MX (1) MX369491B (fr)
MY (1) MY176489A (fr)
NZ (1) NZ722326A (fr)
PE (1) PE20160844A1 (fr)
PH (1) PH12016500953A1 (fr)
PL (2) PL3087071T3 (fr)
PT (2) PT3087071T (fr)
RS (2) RS61479B1 (fr)
SG (1) SG11201605097SA (fr)
SI (2) SI3087071T1 (fr)
SM (2) SMT201800643T1 (fr)
TN (1) TN2016000238A1 (fr)
TW (2) TWI726544B (fr)
UY (1) UY35916A (fr)
WO (1) WO2015100282A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961747B1 (fr) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Composés de carbazole utiles en tant qu'inhibiteurs de bromodomaine
MX379463B (es) 2013-11-08 2025-03-10 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
MX369491B (es) * 2013-12-24 2019-11-11 Bristol Myers Squibb Co Compuestos tricíclicos como agentes anticancerígenos.
US9580430B2 (en) * 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
ES2770349T3 (es) 2015-05-12 2020-07-01 Bristol Myers Squibb Co Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
MA42459A (fr) * 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
KR20180081507A (ko) * 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. 브로모도메인 저해제와 관문 차단의 조합 요법
JP6855505B2 (ja) * 2016-01-20 2021-04-07 ニンボー ウェンダ ファーマー テクノロジー エルティーディー． ブロモドメイン阻害剤としてのカルボリン誘導体
WO2017124934A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline contenant de la phosphine servant d'inhibiteur de bromodomaine
JP2019508494A (ja) * 2016-02-05 2019-03-28 チーア タイ ティエンチン ファーマシューティカル グループ カンパニー，リミティド ブロモドメインタンパク質阻害剤の三環式化合物、並びにその製造、医薬組成物及び使用
AU2017228329B2 (en) 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018086605A1 (fr) 2016-11-10 2018-05-17 山东罗欣药业集团股份有限公司 Composé macrocyclique azoté, son procédé de préparation, sa composition pharmaceutique et son application
CN106905347B (zh) * 2017-04-18 2019-04-16 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
CN111356695B (zh) * 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
WO2020001152A1 (fr) * 2018-06-25 2020-01-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Composés tricycliques
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (fr) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Méthodes de traitement du cancer comprenant l'administration d'un modulateur du récepteur des glucocorticoïdes et d'un agent chimiothérapeutique anticancéreux
WO2020200284A1 (fr) * 2019-04-04 2020-10-08 上海华汇拓医药科技有限公司 Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CA3152923A1 (fr) 2019-09-30 2021-04-08 Keisuke Yamamoto Agent de degradation de bet
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022156757A1 (fr) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Composés tricycliques en tant qu'agents anticancéreux
JP2024507938A (ja) * 2021-02-25 2024-02-21 インパクト バイオメディシンズ インコーポレイテッド 骨髄線維症の治療としてのｂｅｔ阻害剤の使用
JP2024517608A (ja) * 2021-05-06 2024-04-23 ラジエル セラピューティクス エルティーディー． 結晶性カルバゾール誘導体
WO2024099441A1 (fr) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Dégradeur de protéine à bromodomaines et domaine extra-terminal (bet)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014080A1 (fr) * 1992-01-15 1993-07-22 E.I. Du Pont De Nemours And Company Fongicides heterocycliques pontes
WO2005039569A1 (fr) 2003-10-18 2005-05-06 Bayer Healthcare Ag Derives de 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole substitues en 5 et composes associes utilises en tant que gaba-agonistes dans le traitement de l'incontinence urinaire et des maladies associees
US20070269420A1 (en) * 2003-11-24 2007-11-22 Chunduru Srinivas K Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2602777C (fr) 2005-03-25 2018-12-11 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
BR122020016659B8 (pt) 2005-05-10 2021-07-27 Incyte Holdings Corp moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
EP2370407B1 (fr) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazoles et carbolines en tant qu'inhibiteurs de kinase
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
SI2949670T1 (sl) 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba
US8754079B2 (en) 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
ES2706412T3 (es) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
EP2582698B1 (fr) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
CA2810359C (fr) 2010-09-09 2021-06-22 Pfizer Inc. Molecules de liaison 4-1bb
KR20140099556A (ko) * 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
US8580399B2 (en) * 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (fr) 2011-04-15 2018-03-17
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
CN103827109A (zh) * 2011-09-28 2014-05-28 出光兴产株式会社 有机电致发光元件用材料及使用了该材料的有机电致发光元件
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
KR20150047593A (ko) 2012-08-31 2015-05-04 파이브 프라임 테라퓨틱스, 인크. 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2961747B1 (fr) * 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Composés de carbazole utiles en tant qu'inhibiteurs de bromodomaine
US9675697B2 (en) * 2013-03-11 2017-06-13 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
MX369491B (es) * 2013-12-24 2019-11-11 Bristol Myers Squibb Co Compuestos tricíclicos como agentes anticancerígenos.

Also Published As

Publication number Publication date
HUE054183T2 (hu) 2021-08-30
PL3087071T3 (pl) 2019-03-29
PE20160844A1 (es) 2016-09-03
ES2857848T3 (es) 2021-09-29
PL3466949T3 (pl) 2021-05-31
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
CN106029663B (zh) 2018-06-01
LT3466949T (lt) 2021-03-25
MX2016007928A (es) 2016-08-03
US20160318928A1 (en) 2016-11-03
EP3087071B1 (fr) 2018-09-05
MX369491B (es) 2019-11-11
SMT202100165T1 (it) 2021-05-07
CL2016001629A1 (es) 2017-02-17
BR112016013744A2 (fr) 2017-10-03
HRP20210212T8 (hr) 2021-08-20
SI3466949T1 (sl) 2021-03-31
CA2934953A1 (fr) 2015-07-02
CN108558871A (zh) 2018-09-21
AU2014369982A1 (en) 2016-08-04
CN106029663A (zh) 2016-10-12
IL246359A0 (en) 2016-08-31
HRP20181849T1 (hr) 2018-12-28
EA201990240A1 (ru) 2019-06-28
EP3466949A1 (fr) 2019-04-10
HRP20210212T1 (hr) 2021-07-09
JP6466456B2 (ja) 2019-02-06
UY35916A (es) 2015-06-30
JP2017505762A (ja) 2017-02-23
SG11201605097SA (en) 2016-07-28
DK3087071T3 (da) 2019-01-02
EA201691070A1 (ru) 2016-11-30
SMT201800643T1 (it) 2019-01-11
TN2016000238A1 (en) 2017-10-06
TW201609725A (zh) 2016-03-16
CY1121076T1 (el) 2019-12-11
NZ722326A (en) 2019-09-27
AU2014369982B2 (en) 2019-04-18
BR112016013744B1 (pt) 2022-08-30
AR123996A2 (es) 2023-02-01
IL246359B (en) 2020-04-30
RS58014B1 (sr) 2019-02-28
JP2019070014A (ja) 2019-05-09
PH12016500953A1 (en) 2016-06-27
CY1124061T1 (el) 2022-05-27
RS61479B1 (sr) 2021-03-31
PT3466949T (pt) 2021-02-25
AR099379A1 (es) 2016-07-20
TWI726544B (zh) 2021-05-01
EA032469B1 (ru) 2019-05-31
TWI736517B (zh) 2021-08-21
KR20160095168A (ko) 2016-08-10
DK3466949T3 (da) 2021-03-15
EP3087071A1 (fr) 2016-11-02
MY176489A (en) 2020-08-12
ES2698998T3 (es) 2019-02-06
CA2934953C (fr) 2022-09-20
SI3087071T1 (sl) 2018-11-30
CN108558871B (zh) 2022-02-18
KR102457145B1 (ko) 2022-10-19
WO2015100282A1 (fr) 2015-07-02
PT3087071T (pt) 2018-11-29
EP3466949B1 (fr) 2020-12-23
HUE041719T2 (hu) 2019-05-28
TW202028203A (zh) 2020-08-01
JP6675501B2 (ja) 2020-04-01

Similar Documents

Publication Publication Date Title
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
CA2871471C (fr) Inhibiteurs d'adn pk
IN2015DN01156A (fr)
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA35638B1 (fr) 2-thiopyrimidinones
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA38925A1 (fr) Dérivés de phénylalanine substitués
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
UA119446C2 (uk) 1,2,4-ТРИАЗОЛО[4,3-а]ПІРИДИНОВІ СПОЛУКИ ТА ЇХ ЗАСТОСУВАННЯ ЯК ПОЗИТИВНИХ АЛОСТЕРИЧНИХ МОДУЛЯТОРІВ РЕЦЕПТОРІВ MGLUR2
MX2009010225A (es) Nuevos compuestos 707 y sus usos.
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle